CYTEIR THERAPEUTICS
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
CYTEIR THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2012-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cyteir.com
Total Employee:
11+
Status:
Active
Contact:
312-953-3651
Total Funding:
156.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
7 Hills Pharma
7 Hills Pharma is developing novel immunotherapies for the treatment Of cancer.
Ankyra
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.
Avro
Avro Life Science is developing skin patches for generic drug delivery, focusing on therapeutics for children and the elderly.
Brise Pharma
Brise Pharma operates in the scientific research and technical service industry.
Cadence Health
Cadence, a pharma startup, aims to switch a birth control pill over-the-counter to create easy and affordable access to contraceptives.
CaroGen
CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
Cartesian Therapeutics
Pioneering Potent, Safer Cell Therapy in and Beyond Oncology
EIP Pharma
EIP Pharma Provides Healthcare Services.
EpiVario
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
F-Star Therapeutics
F-Star Therapeutics is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.
FTEX
FTEX Develops next-generation GaNFET based Electric Vehicle (EV) powertrains that extend the range and power of EVs by up to 30%.
HDT Bio
IMMUNE THERAPY FOR ALL: We’re transforming inventive immunotherapies for oncology and infectious disease.
HQS Quantum Simulations
HQS Quantum Simulations is developing quantum algorithms to predict molecular properties for specialty chemicals & pharmaceutical companies.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Innoviva
Innoviva is committed to building long-lasting value and improving patient care.
Intabio
Intabio is a developer of a real-time protein analytics platform used to transform the development of biotherapeutic drug.
JOINN Biologics
Your premier CDMO for biologics drug development and manufacturing, from early development, to IND, to commercial stage.
LB Pharmaceuticals
LB Pharmaceuticals specializes in developing a treatment for schizophrenia.
Mana Therapeutics
Next-Generation Immunotherapies
MyMeds&Me
My Meds & Me provides a web-based solution for the capture of adverse event, product complaint.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Nivagen Pharmaceuticals, Inc.
Nivagen engages in the development, acquisition, and sales of generic prescription drugs and over the counter products.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
PanCryos
PanCryos develops a next generation stem cell derived allogenic cell therapy or Type 1 diabetes.
Galectin Therapeutics
Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.
Recludix Pharma
Recludix pharma is a developing platform to treat cancer patients.
RUTI Immune
RUTI Immune developing a vaccine against Covid-19 and other known or unknown viruses.
Sisu Pharma
Sisu Pharma is developing drugs against a new target to treat prostate cancer.
T-knife
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Vibliome
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
XellSmart
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
Current Advisors List
Board_observer
Board_member
Board_member
Board_member
2018-01-01
Board_member
2012-06-01
Board_member
Current Employees Featured
Kevin Mills Co-Founder @ Cyteir Therapeutics
Co-Founder
2012-01-01
Tim Romberger Co-Founder @ Cyteir Therapeutics
Co-Founder
2012-06-01
Markus Renschler President & Chief Executive Officer @ Cyteir Therapeutics
President & Chief Executive Officer
Andrew Gengos Chief Business Officer @ Cyteir Therapeutics
Chief Business Officer
2020-02-01
Paul Secrist Chief Scientific Officer @ Cyteir Therapeutics
Chief Scientific Officer
Barbara Wan VP, Research and Development Project Leadership @ Cyteir Therapeutics
VP, Research and Development Project Leadership
Jean-Marc Lapierre VP, Chemistry @ Cyteir Therapeutics
VP, Chemistry
Krisztina Nemenyi Senior Vice President of Regulatory Affairs and Quality @ Cyteir Therapeutics
Senior Vice President of Regulatory Affairs and Quality
2022-01-01
Adam Veness General Counsel @ Cyteir Therapeutics
General Counsel
2022-04-01
Founder
Stock Details
Investors List
CaaS Capital Management
CaaS Capital Management investment in Series C - Cyteir Therapeutics
Venrock
Venrock investment in Series C - Cyteir Therapeutics
Droia Ventures
Droia Ventures investment in Series C - Cyteir Therapeutics
Ample Plus Fund
Ample Plus Fund investment in Series C - Cyteir Therapeutics
Ally Bridge Group
Ally Bridge Group investment in Series C - Cyteir Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Series C - Cyteir Therapeutics
Avidity Partners
Avidity Partners investment in Series C - Cyteir Therapeutics
Acuta Capital Partners
Acuta Capital Partners investment in Series C - Cyteir Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Cyteir Therapeutics
Novo Holdings
Novo Holdings investment in Series C - Cyteir Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-03 | Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality |
Official Site Inspections
http://www.cyteir.com Semrush global rank: 5.15 M Semrush visits lastest month: 1.57 K
- Host name: 91.195.240.13
- IP address: 91.195.240.13
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Cyteir Therapeutics"
Cancer’s Vulnerability Is Our Strength - Cyteir
Feb 10, 2021 cyteir.com Lead Program: CYT-0851, a Selective Inhibitor of RAD51-Mediated Homologous Recombination ... Our mission at Cyteir is to build a world-class oncology …See details»
Cyteir Therapeutics - Crunchbase Company Profile
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. …See details»
Home - Cyteir
Cyteir Therapeutics ceased operations in 2024. Past press releases can be found here and past SEC filings can be found here. Inquiries should be directed to: …See details»
Cyteir Therapeutics - Funding, Financials, Valuation & Investors
Cyteir Therapeutics is registered under the ticker NASDAQ:CYT . Their stock opened with $18.00 in its Jun 17, 2021 IPO. Cyteir Therapeutics is funded by 14 investors. CaaS Capital …See details»
Small molecules that selectively target RAD51 in cells defined by ...
128 Spring Street | Building A, Suite 510 | Lexington, MA 02421 | P: 857- 285-4140 | F: 857-285-4141 | www.cyteir.com . The company. Cyteir Therapeutics is a clinical stage VC- , funded, …See details»
Cyteir Therapeutics - Contacts, Employees, Board Members
Organization. Cyteir Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Contacts 26. About. Cyteir Therapeutics has 7 current …See details»
Cyteir Therapeutics Overview | SignalHire Company Profile
Cyteir Therapeutics is a public company that has been in the industry for 12 years. The company currently specializes in the Research, Biotechnology areas. The position of the President & …See details»
Cyteir Therapeutics - Org chart - The Org
Explore Cyteir Therapeutics' organizational chart. Discover current team members including executives, board members, and advisors.See details»
Organization: Cyteir Therapeutics - Cbonds.com
Organization: Cyteir Therapeutics Organization name. Cyteir Therapeutics, Inc. ... Cyteir Therapeutics, Inc. operates as a pharmaceutical company. The Company discovers, develops, …See details»
Cyteir Therapeutics - The Org
Through a unique cancer treatment approach, Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, …See details»
Cyteir Therapeutics
Feb 25, 2025 Cyteir Therapeutics was founded by Greg Verdine in 2014. We have a team of scientists, technologists and clinicians pioneering a new generation of therapeutic cancer …See details»
Cyteir Therapeutics' Leadership Team - Team members and org …
The leaders at Cyteir Therapeutics have experience in a variety of industries, including finance, accounting, and oncology. They have also worked for companies such as Wave Life Sciences, …See details»
Cyteir - Company Profile - Tracxn
Feb 17, 2025 Cyteir. has raised a total funding of $155M over 7 rounds. Its first funding round was on Jul 15, 2014. What are the most recent funding rounds of Cyteir? Its latest funding …See details»
Cyteir finally calls it quits after months of cost cutting - Fierce …
Jun 30, 2023 Cyteir established itself on the biotech scene in 2018 when it netted $29 million in series B funding and plucked Renschler to steer the ship after he led global hematology work …See details»
Cyteir Therapeutics Inc (CYT-Q) Profile - The Globe and Mail
See the company profile for Cyteir Therapeutics Inc (CYT-Q) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Cyteir Therapeutics Company Overview, Contact Details ... - LeadIQ
Feb 11, 2021 Key Personnel Expansion Cyteir Therapeutics has recently bolstered its leadership team by hiring key personnel such as the Chief Financial Officer, General Counsel, and board …See details»
Cyteir Therapeutics - Tech Stack, Apps, Patents & Trademarks
Feb 2, 2025 The intellectual property of Cyteir Therapeutics includes 22 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. …See details»
Cyteir Therapeutics - Work in biotech
Cyteir Therapeutics is using the principle of synthetic lethality to develop cancer therapies. Synthetic lethality is a mechanism used to exploit weaknesses in cancer cells that are not …See details»
Cyteir Therapeutics - Overview, News & Similar companies
Mar 7, 2024 LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT …See details»
Cyteir’s $126 Million IPO Shows The Biotech Boom Is Far From Over
Jun 22, 2021 As Cyteir Therapeutics goes public, it’s clear that the biotech IPO boom is far from over following a busy 2020 and 2021 so far.The company itself is an...See details»